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Abstract 
In Iraqi women theirs problem related to polycystic ovary syndrome, therefor the present study focus in these 
women patients and aimed to determine the hormonal changes in the class of these women the hormonal 
changes included  Follicle-stimulating hormone FSH, Luteinizing hormone LH, and Prolactin (PRL) and study 
the correlation between theme using statistical analysis, to achieve good results from current research 30 
specimens of blood   were  collected  from 45  patients  with  PCOS  and  30  healthy  between  27  and 44  old  
year's  consider- as  control  samples   attending  the  private  clinic  in  Baghdad governorate   from  the period  
November  2015  to  June  2016.  All samples were inoculated  to  study  different  characteristics  of  hormones.  
The   results  obtained  from  statistical  analysis  appeared  that  there's  significant difference  between  the  
studied  hormones  P ≥ 0.05  also  there's  high significant  difference  in  the  titration  of  the  same  hormone  
in the  patients  based  on  the  age of  women  patients' blood was hormonal assay results revealed a gradual 
decrease in serum FSH levels with a concomitant increase in Serum LH hormone level , when compared with 
control healthy also there's depression in Prolactin in thyroid  cancer  patients  Compared with  control healthy.    
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1. Introduction  
Polycystic ovary syndrome,(PCOS) is the most common cause of anovulation,  Infertility and hyper and 
rogenism in women, affecting between 5 and 10% of women of reproductive age worldwide[1]. Chronic 
anovulation is a common disorder in women of reproductive age. Some women with chronic anovulation also 
have high androgen levels or polycystic ovary appearance on ultrasound examination, and are diagnosed as 
having polycystic ovary syndrome (PCOS) by the 2003 Rotterdam criteria [2]. The pathogenesis of chronic 
anovulation, with or without PCOS, is poorly understood. A high incidence of similar phenotypes in family 
members of PCOS patients suggests that genetics may play a role [3]. Though the polymorphisms in genes 
encoding sex hormones and their receptors have been investigated, results are still conflicting [4,5]. Assessing 
hormone levels serves two major purposes. First of all, it helps to rule out any other problems that might be 
causing the symptoms. Secondly, together with an ultrasound and personal and family histories, it helps your 
doctor confirm that  you do  have PCOS . Most often, the following hormone  levels are measured  when  
considering  a PCOS  diagnosis:  Lutenizing hormone (LH), Follicle  Stimulating hormone (FSH), Total and 
Free Testosterone , Dehydroepiandrosterone sulfate (DHEAS)  , Prolactin, rostenedione and Progesterone. LH , 
FSH and prolactin are the hormones that encourage ovulation[6]. Both LH and FSH are secreted by the pituitary 
gland in the brain. At the beginning of the cycle, LH and FSH levels usually-range between about 5-20 mlU/ml. 
Most women have about equal amounts-of LH and FSH during the early part of their cycle. However, there is a 
LH-surge in which the amount of LH increases to about 25-40  mlU/ml 24 hours before ovulation occurs . Once  
the egg is released by the ovary, the LH levels goes back down [7].     
While many women with  PCOS still have  LH and FSH still within the  5-20 mlU/ml  range , their LH level is 
often two or three-times-that-of-the FSH-level . It is typical for women with PCOS to have an LH level of about 
18 mlU/ml and  FSH-level-of about 6 mlU/ml (both levels fall within the normal range of 5-20 mlU/ml)[8]. This 
situation is called an elevated LH to FSH  ratio or a ratio of  3:1 . This  change in  the  LH  to  FSH  ratio is  
enough to  disrupt ovulation. While this used to be considered-an  important  aspect in  diagnosing  PCOS , it   is  
now   considered   less  useful   in  diagnosing   PCOS ,  but  is   still   helpful   when   looking   at   the   overall   
picture [9]. 
The current study designed to investigate some hormonal changes of polycystic ovary syndrome women patients 
based on hormonal abnormality and compared with control. 
2. Material and Methods   
Thirty (30) specimens  of  blood were collected from 45 women patients  with Polycystic ovary syndrome 
(PCOS) and 30 healthy between 27 and 44 years old attending the Private clinics hospital  from the period from 
November 2015 to June 2016. All samples were inoculated to study different characteristics of  hormons. At the 
experiment blood samples were drawn and serum was collected by centrifugation. Follicle-stimulating hormone 
(FSH)  concentrations were measured and Lutenizing hormone (LH), and Prolactin in serum by ELIZA kits 
(Beckman-France),  as presented in standard Assay [10] procedures respresented in figure 1 . The results were 
analyzed using one-way analysis of variance (ANOVA), the level of statistic was set at P<0.05(11).  
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mIU/mlFSH, Procedure for  
Format the micro plate wells for each serum reference, control and patient specimen 
 
• Add 50µL of the appropriate serum reference or specimen into each well 
 
 
Incubation 15 minutes at room temperatures 
 
Add50µl stop solution to each 
 
Swirl the micro plate 20-30 second 
 
Read the absorbance in each wells at 450 nm 
 
Procedure for LH 
Format the micro plate wells for each serum reference, control and patient specimen 
 
• Add 25µl of the appropriate serum reference or specimen into each well 
 
Add 100µl of working reagent A, LH enzyme reagent  to all wells 
 
   Swirl the micro plate 20-30 second 
 
Incubation 60 minutes at room temperatures 
 
Discard the contents of the micro plate 
Swirl the micro plate 20-30 second 
 
Read the absorbance in each wells at 450 nm 
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Procedure for Prolactin  
Format the micro plate wells for each serum reference, control and patient specimen 
 
• Add 50μl of the appropriate serum reference or specimen into each well 
 
 
Add 100µl of prolactin enzyme reagent  to all wells 
 
 
Swirl the micro plate 20-30 second 
 
Read the absorbance in each wells at 450 nm 
 
Figure 1: procedure of hormones analysis subjected during the present study 
 
Statistical  Analysis: 
The values of the investigated parameters were given in terms of mean ± standard error, and differences 
between means were assessed by analysis of variance (ANOVA) using  SAS  computer  program version 7.5. 
Differences in results were considered significant at probability value equal or less than 0.05 and 0.001. 
3. Results and Discussion 
Our findings support  to  the relationship with  hormonal  changes.  To  study  the  disorder  of  hormones  in  
the   women  patients  with  PCOS   The analysis  of  blood  subjected  and  appeared that  theirs  significant 
difference between  the healthy group  and  women  with PCOS   patients  during  the period of study   as  
appeared  in table (1).   
Hormonal  changes  play  important  roles  in  the patients  with  PCOS Table (1) Represented and summarized 
the  hormonal  profile of  women  with -PCOS subjected in  the  study  compared  with  healthy  in  the  study  
groups  the mean  value  concentration  of   FSH mIU/ml in control   6.52mIU/ml   while the average  in  
patients  groups   reach  to  16.0 mIU/ml   the  LH mIU/ml concentrations in  PCOS  patients  between  6.9-
21.4.The  results  showed a general  trend  for   FSH  values  to  increase  in  patients group, this increase 
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reached statistical significance (P<0.05) where  the average  values of serum Prolactin in  control group   was 
9.2 while  the average  concentrations  in patients was   5.61 its ranged  between 1.4 to 12.3 results appeared that 
prolactin decrease in patients when compared with the control. 
Table 1: Average of Follicular stimulating hormone (FSH) , (LH) and (Prolactine)  in women patients with 
PCOS compare with healthy control. 
 
Figures 2,3 and 4, summarize the concentrations profile of the three studied hormones FSH, mIU/ml, LH3 
mIU/ml and prolactin in women patients with polycystic ovary syndrome (PCOS). 
 
Figure 2: Follicle-stimulating hormone (FSH) in women patients with PCOS compared with healthy. 
 
Figure 3: Lutenizing hormone (LH) mIU/ml in patients with PCOS compared with healthy. 
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Figure 4: Prolactin hormon mIU/ml in patients with PCOS compared with healthy. 
Statistical correlations of Follicle-stimulating hormone FSH, Luteinizing hormone LH, and Prolactin (PRL)           
Our results clear the mode of correlations between the Follicle stimulating hormone FSH, Luteinizing hormone 
LH, and Prolactin (PRL) in the PCOS women patients.  Studied statically according to the Pearson correlation as 
shown at the table (2), there was a significant correlation between studied hormones (p 0.001). 
Table 2: The correlations between the three Follicle stimulating hormone FSH Luteinizing hormone LH, and 
Prolactin (PRL) hormoes 
Marker  FSH LH PRL 
 
 
FSH 
Pearson 
Correlation 
_ 0.348 
*** 
- 
Sig.(2-tailed) _ 0.005 - 
No. 30 30 30 
 
 
LH  
Pearson 
Correlation 
0.348 
*** 
_ 23.09 
Sig.(2-tailed) 0.005 _ 37.9 
No. 30 30 30 
PRL Pearson 
Correlation 
23.4 11 0.348 
*** 
Sig.(2-tailed) 45.9 39 0.005 
No. 30 30 30 
***P <0.001 
**Pearson's correlation between two variables is defined as the covariance of the two variables divided by the 
product of their standard deviations. 
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Our  present  results  may  be  related  to  Polycystic  ovary  syndrome (PCOS) represents  the  most common  
endocrinopathy  of women  of  reproductive age [12]. Although  descriptions  of  polycystic  ovaries  date back  
to  the  early 1700s,  variable  degrees of virilization, menstrual  abnormalities, and bilaterally enlarged  
polycystic  ovaries  form  the  basis  for  the definition of PCOS [13]. In addition to the clinical manifestations  
of  infertility and virilization, metabolic consequences  of  PCOS include  obesity [14]. To date, there is no 
overall consensus on the definition of PCOS or the criteria used for diagnosis [15]. PCOS is  a  disorder  of  
androgen  excess  or  hyperandrogenism  with  the  following clinical findings: hyperandrogenism (hirsuitism 
and/or hyperandrogenemia),  ovarian  dysfunction   (oligo-anovulation and/or polycystic ovaries), and the  
exclusion  of  other  androgen  excess related Disorders of hormones [16].  The area of active  investigation in 
PCOS has  been the ovary [17]. This analysis   has focused  primarily on the  granulosa and  theca  interstitial 
cells  of the  small Graafian  follicles  that accumulate in  the  cortex  of PCOS ovaries [18].  
4. Conclusion  
Our study showed that there was significant difference between PCOSr patients and healthy human at the 
studied group  may be due to molecular changes  that it is more precise and less consuming time in study of 
thyroid cancer and this result may help in control and develop treatment for these cases. 
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